Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

Eline Boon; Winette T A van der Graaf; Hans Gelderblom; Margot E T Tesselaar; Robert J.J. van Es; Sjoukje F Oosting; Remco de Bree; Esther van Meerten; Ann Hoeben; Ludi E. Smeele; Stefan M. Willems; Max J H Witjes; Jan Buter; Robert J Baatenburg de Jong; Uta E. Flucke; Petronella G.M. Peer; Judith V.M.G. Bovée; Carla M L Van Herpen

doi:10.1002/hed.24556

Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

Eline Boon, Winette T A van der Graaf, Hans Gelderblom, Margot E T Tesselaar, Robert J.J. van Es, Sjoukje F Oosting, Remco de Bree, Esther van Meerten, Ann Hoeben, Ludi E. Smeele, Stefan M. Willems, Max J H Witjes, Jan Buter, Robert J Baatenburg de Jong, Uta E. Flucke, Petronella G.M. Peer, Judith V.M.G. Bovée, Carla M L Van Herpen

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively). Conclusion: In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant chemotherapy in patients amenable to chemotherapy.

Original language	English
Pages (from-to)	140-146
Number of pages	7
Journal	Head and Neck
Volume	39
Issue number	1
DOIs	https://doi.org/10.1002/hed.24556
Publication status	Published - 1 Jan 2017

Keywords

(neo-)adjuvant
chemotherapy
head and neck neoplasms
mandible
maxilla
osteosarcoma

Access to Document

10.1002/hed.24556

ImpactFinal published version, 295 KB

Cite this

Boon, E., van der Graaf, W. T. A., Gelderblom, H., Tesselaar, M. E. T., van Es, R. J. J., Oosting, S. F., de Bree, R., van Meerten, E., Hoeben, A., Smeele, L. E., Willems, S. M., Witjes, M. J. H., Buter, J., Baatenburg de Jong, R. J., Flucke, U. E., Peer, P. G. M., Bovée, J. V. M. G., & Van Herpen, C. M. L. (2017). Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head and Neck, 39(1), 140-146. https://doi.org/10.1002/hed.24556

@article{89182be5d38d4525b049c882a8ae2585,

title = "Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults",

abstract = "Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively). Conclusion: In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant chemotherapy in patients amenable to chemotherapy.",

keywords = "(neo-)adjuvant, chemotherapy, head and neck neoplasms, mandible, maxilla, osteosarcoma",

author = "Eline Boon and {van der Graaf}, {Winette T A} and Hans Gelderblom and Tesselaar, {Margot E T} and {van Es}, {Robert J.J.} and Oosting, {Sjoukje F} and {de Bree}, Remco and {van Meerten}, Esther and Ann Hoeben and Smeele, {Ludi E.} and Willems, {Stefan M.} and Witjes, {Max J H} and Jan Buter and {Baatenburg de Jong}, {Robert J} and Flucke, {Uta E.} and Peer, {Petronella G.M.} and Bov{\'e}e, {Judith V.M.G.} and {Van Herpen}, {Carla M L}",

year = "2017",

month = jan,

day = "1",

doi = "10.1002/hed.24556",

language = "English",

volume = "39",

pages = "140--146",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley & Sons Inc.",

number = "1",

}

Boon, E, van der Graaf, WTA, Gelderblom, H, Tesselaar, MET, van Es, RJJ, Oosting, SF, de Bree, R, van Meerten, E, Hoeben, A, Smeele, LE, Willems, SM, Witjes, MJH, Buter, J, Baatenburg de Jong, RJ, Flucke, UE, Peer, PGM, Bovée, JVMG & Van Herpen, CML 2017, 'Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults', Head and Neck, vol. 39, no. 1, pp. 140-146. https://doi.org/10.1002/hed.24556

TY - JOUR

T1 - Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

AU - Boon, Eline

AU - van der Graaf, Winette T A

AU - Gelderblom, Hans

AU - Tesselaar, Margot E T

AU - van Es, Robert J.J.

AU - Oosting, Sjoukje F

AU - de Bree, Remco

AU - van Meerten, Esther

AU - Hoeben, Ann

AU - Smeele, Ludi E.

AU - Willems, Stefan M.

AU - Witjes, Max J H

AU - Buter, Jan

AU - Baatenburg de Jong, Robert J

AU - Flucke, Uta E.

AU - Peer, Petronella G.M.

AU - Bovée, Judith V.M.G.

AU - Van Herpen, Carla M L

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively). Conclusion: In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant chemotherapy in patients amenable to chemotherapy.

AB - Background: There is an ongoing debate about the value of (neo-)adjuvant chemotherapy in high- and intermediate-grade osteosarcoma of the head and neck. Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed. Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5-year overall survival (OS) was 55%. In 50 patients with surgically resected high- or intermediate-grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively). Conclusion: In patients younger than 75 years of age with surgically resected high- and intermediate-grade osteosarcoma of the head and neck, treatment with (neo-)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo-)adjuvant chemotherapy in patients amenable to chemotherapy.

KW - (neo-)adjuvant

KW - chemotherapy

KW - head and neck neoplasms

KW - mandible

KW - maxilla

KW - osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84992455491&partnerID=8YFLogxK

U2 - 10.1002/hed.24556

DO - 10.1002/hed.24556

M3 - Article

C2 - 27507299

AN - SCOPUS:84992455491

SN - 1043-3074

VL - 39

SP - 140

EP - 146

JO - Head and Neck

JF - Head and Neck

IS - 1

ER -

Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this